Evaluate Safety & Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults

Exclusion Criteria

• •Administration of other licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrolment in this study.
• •Planned administration of a vaccine not foreseen by the study protocol up to 30 days after vaccination
• •Planned administration of an influenza vaccine other than the study vaccines during the entire study period
• •Any vaccination against influenza since January 2007
• •Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.
• •Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
• •History of hypersensitivity to a previous dose of influenza vaccine
• •History of allergy or reactions likely to be exacerbated by any component of the vaccine(s)
• •Acute (active) clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or pre-existing laboratory screening tests
• •Acute disease at the time of enrolment
• •Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period
• •Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days prior to vaccination, or planned use during the study period
• •Any medical conditions in which IM injections are contraindicated
• •Pregnant or lactating female, or planning to become pregnant or to discontinue contraceptive precautions.